191 related articles for article (PubMed ID: 35946383)
1. Dendritic Cell-Based Vaccines Against Cancer: Challenges, Advances and Future Opportunities.
Fu C; Ma T; Zhou L; Mi QS; Jiang A
Immunol Invest; 2022 Nov; 51(8):2133-2158. PubMed ID: 35946383
[TBL] [Abstract][Full Text] [Related]
2. Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment.
Fu C; Jiang A
Front Immunol; 2018; 9():3059. PubMed ID: 30619378
[TBL] [Abstract][Full Text] [Related]
3. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
4. DC-Derived Exosomes for Cancer Immunotherapy.
Yao Y; Fu C; Zhou L; Mi QS; Jiang A
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359569
[TBL] [Abstract][Full Text] [Related]
5. DC-Based Vaccines for Cancer Immunotherapy.
Fu C; Zhou L; Mi QS; Jiang A
Vaccines (Basel); 2020 Nov; 8(4):. PubMed ID: 33255895
[TBL] [Abstract][Full Text] [Related]
6. Plasmacytoid Dendritic Cells and Cancer Immunotherapy.
Fu C; Zhou L; Mi QS; Jiang A
Cells; 2022 Jan; 11(2):. PubMed ID: 35053338
[TBL] [Abstract][Full Text] [Related]
7. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
[TBL] [Abstract][Full Text] [Related]
8. Beyond cDC1: Emerging Roles of DC Crosstalk in Cancer Immunity.
Noubade R; Majri-Morrison S; Tarbell KV
Front Immunol; 2019; 10():1014. PubMed ID: 31143179
[TBL] [Abstract][Full Text] [Related]
9. Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103
Zhou Y; Slone N; Chrisikos TT; Kyrysyuk O; Babcock RL; Medik YB; Li HS; Kleinerman ES; Watowich SS
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32273347
[TBL] [Abstract][Full Text] [Related]
10. Genetic vaccines to potentiate the effective CD103+ dendritic cell-mediated cross-priming of antitumor immunity.
Zhang Y; Chen G; Liu Z; Tian S; Zhang J; Carey CD; Murphy KM; Storkus WJ; Falo LD; You Z
J Immunol; 2015 Jun; 194(12):5937-47. PubMed ID: 25972487
[TBL] [Abstract][Full Text] [Related]
11. Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141
Masterman KA; Haigh OL; Tullett KM; Leal-Rojas IM; Walpole C; Pearson FE; Cebon J; Schmidt C; O'Brien L; Rosendahl N; Daraj G; Caminschi I; Gschweng EH; Hollis RP; Kohn DB; Lahoud MH; Radford KJ
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32737142
[TBL] [Abstract][Full Text] [Related]
12. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses.
Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA
Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391
[TBL] [Abstract][Full Text] [Related]
13. Outer membrane vesicles engineered to express membrane-bound antigen program dendritic cells for cross-presentation to CD8
Schetters STT; Jong WSP; Horrevorts SK; Kruijssen LJW; Engels S; Stolk D; Daleke-Schermerhorn MH; Garcia-Vallejo J; Houben D; Unger WWJ; den Haan JMM; Luirink J; van Kooyk Y
Acta Biomater; 2019 Jun; 91():248-257. PubMed ID: 31003032
[TBL] [Abstract][Full Text] [Related]
14. Plasmacytoid dendritic cells cross-prime naive CD8 T cells by transferring antigen to conventional dendritic cells through exosomes.
Fu C; Peng P; Loschko J; Feng L; Pham P; Cui W; Lee KP; Krug AB; Jiang A
Proc Natl Acad Sci U S A; 2020 Sep; 117(38):23730-23741. PubMed ID: 32879009
[TBL] [Abstract][Full Text] [Related]
15. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer.
Huang L; Rong Y; Tang X; Yi K; Qi P; Hou J; Liu W; He Y; Gao X; Yuan C; Wang F
Mol Cancer; 2022 Feb; 21(1):45. PubMed ID: 35148751
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cell biology and its role in tumor immunotherapy.
Wang Y; Xiang Y; Xin VW; Wang XW; Peng XC; Liu XQ; Wang D; Li N; Cheng JT; Lyv YN; Cui SZ; Ma Z; Zhang Q; Xin HW
J Hematol Oncol; 2020 Aug; 13(1):107. PubMed ID: 32746880
[TBL] [Abstract][Full Text] [Related]
17. Engineering anti-cancer nanovaccine based on antigen cross-presentation.
Warrier VU; Makandar AI; Garg M; Sethi G; Kant R; Pal JK; Yuba E; Gupta RK
Biosci Rep; 2019 Oct; 39(10):. PubMed ID: 31652460
[TBL] [Abstract][Full Text] [Related]
18. Trial watch: Dendritic cell (DC)-based immunotherapy for cancer.
Laureano RS; Sprooten J; Vanmeerbeerk I; Borras DM; Govaerts J; Naulaerts S; Berneman ZN; Beuselinck B; Bol KF; Borst J; Coosemans A; Datsi A; Fučíková J; Kinget L; Neyns B; Schreibelt G; Smits E; Sorg RV; Spisek R; Thielemans K; Tuyaerts S; De Vleeschouwer S; de Vries IJM; Xiao Y; Garg AD
Oncoimmunology; 2022; 11(1):2096363. PubMed ID: 35800158
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
20. Tumor-Derived Microvesicles Enhance Cross-Processing Ability of Clinical Grade Dendritic Cells.
Dionisi M; De Archangelis C; Battisti F; Rahimi Koshkaki H; Belleudi F; Zizzari IG; Ruscito I; Albano C; Di Filippo A; Torrisi MR; Benedetti Panici P; Napoletano C; Nuti M; Rughetti A
Front Immunol; 2018; 9():2481. PubMed ID: 30455687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
